For 25 years, Flagship Pioneering has been turning bold ideas into transformative realities — pushing the boundaries of knowledge to create a better future for people and the planet. The people who drive our ecosystem forward share more than ambition — they share a pioneering mindset. Together, we’re not just advancing science; we’re taking bigger leaps that redefine what’s possible. Read why employees of Alltrna, Tessera Therapeutics, and Valo Health pioneer. #BiggerLeaps #WeAreFlagship
Flagship Pioneering
Biotechnology Research
Cambridge, MA 142,276 followers
We are a biotechnology company that invents and builds platform companies that change the world.
About us
Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.
- Website
-
http://www.flagshippioneering.com
External link for Flagship Pioneering
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Founded
- 2000
- Specialties
- life sciences, biotech, therapeutics, diagnostics, sustainability, climate change, artificial intelligence, machine learning, agtech, medicines, therapeutics, biology, entrepreneurship, biotechnology, science, innovation, and ventures
Locations
-
Primary
Get directions
55 Cambridge Parkway
Suite 800E
Cambridge, MA 02142, US
Employees at Flagship Pioneering
Updates
-
In the latest episode of Harvard Business Review's IdeaCast, Flagship Founder & CEO Noubar Afeyan joins Alison Beard to discuss how innovative organizations are built, the distinction between managing risk and managing uncertainty, and what sets breakthrough science apart from incremental progress. Catch the full episode here: https://lnkd.in/gmPaqRhN
-
Flagship Pioneering reposted this
As someone deeply dedicated to advancing women’s health and to Flagship Pioneering’s mission to drive breakthroughs in human health, I was honored to take part in this year’s Massachusetts Conference for Women and introduce Jessica Shepherd, MD, MBA, FACOG, Women’s Wellness & Longevity Expert, CMO at Hers, and Author. She spoke about reclaiming women’s health and redefining longevity. Her messages were both inspiring and galvanizing. Grateful for the opportunity to share this experience with my Flagship colleagues. Moments like these reinforce the momentum and meaningful change we’re working to drive together. #WeAreFlagship #BiggerLeaps
-
-
-
-
-
+1
-
-
Now recruiting for the AI/ML Track.💡 The Flagship Fellowship AI/ML Track is a unique opportunity to creatively apply cutting-edge computational thinking to our company creation process. We're looking for entrepreneurial computational scientists excited to invent and build world-changing companies in AI, technology, and life-sciences. Learn more and apply here: https://lnkd.in/erQQD5AU
-
Flagship Pioneering reposted this
At YourBio, we’re reimagining what the modern blood collection process can and should look like: simpler, easier, and more human. We look forward to continuing this mission with hims & hers. Read more about the agreement announced today, which is subject to customary regulatory approvals and closing conditions: https://lnkd.in/eAA7apMj
-
-
Check out the Boston Business Journal this week, featuring our Founder & CEO, Noubar Afeyan, highlighting Flagship’s 25-year journey of pioneering a new model of company creation. Noubar reflects on the mindset behind our approach, the evolution of the biotech industry, and how Flagship is preparing for the next chapter of innovation. Read the full story here: https://lnkd.in/eVZnj5RQ
-
-
For Giving Tuesday, we’re proud to highlight the many ways our Flagship colleagues have given back this year, alongside partners like Life Science Cares Boston and One8 Applied Learning Hub. Employees have volunteered at our annual Day of Service, hosted a sock drive at Flagship’s 25th Anniversary event, mentored students in STEM, donated food shelf-stable items this fall, and so much more throughout the year!
-
-
The start of Generate’s late-stage clinical trial for its AI-engineered medicine for asthma is yet another powerful example of the transformative impact of generative technologies on biology, producing and accelerating the development of therapies that couldn’t be designed any other way. Recruiting patients from 45 countries, the trial reflects the same global reach and impact of generative AI on drug design.
Progress in #GenerativeBiology becomes real when a molecule performs exactly as it was designed. Today, we announced the initiation of SOLAIRIA, the first global Phase 3 studies of a long-acting anti-TSLP antibody for #SevereAsthma. These studies will evaluate GB-0895, which blocks TSLP — an upstream driver of the inflammatory response in #asthma. Using our generative optimization technology stack, GB-0895 was computationally designed to improve potency and half-life while retaining specificity, supporting a potential every-six-month dosing schedule. This move into #Phase3 demonstrates what programmable biology can enable — design translating into development. Learn more about SOLAIRIA → https://lnkd.in/eMTCZpXC Read our full announcement → https://lnkd.in/e2Q9K7-Y #ClinicalTrials | #RespiratoryHealth
-
-
Tessera’s Gene Writing and delivery technology offers the promise of a one-time, lasting treatment for AATD—addressing the genetic root of a disease for which no such options exist today. This collaboration brings together #FlagshipFounded Tessera’s pioneering science with Regeneron’s industry-leading capabilities in genetics, creating a path toward new possibilities for patients and their families.
Today, we're excited to announce we have entered into a global collaboration with Regeneron to jointly develop and commercialize our lead in vivo program, TSRA-196, for alpha1 anti-trypsin deficiency (AATD). This partnership combines world-class genetic medicine expertise and brings in $150M in upfront cash and equity to Tessera. Read more here: https://lnkd.in/ek-qukyu
-
-
Flagship Pioneering announces Michael Nally, CEO of #FlagshipFounded Generate:Biomedicines and Flagship CEO-Partner, as the recipient of this year’s Bigger Leaps Award. At Generate, Mike has paired scientific vision with operational discipline, and — just as importantly — has built a culture that turns aspiration into achievement, uniting more than 300 “Generators” around a shared mission to engineer the future of medicine. For more: https://bit.ly/3Ki9qHn
-